Home > Boards > US Listed > Medical - Healthcare > Acasti Pharma, Inc (ACST)

well, i meant, phase 3 results being published

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jammastermike Member Profile
 
Followed By 2
Posts 262
Boards Moderated 0
Alias Born 05/01/18
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/11/2020 8:01:17 AM
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States... GlobeNewswire Inc. - 3/11/2020 8:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/28/2020 5:09:23 PM
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements GlobeNewswire Inc. - 2/28/2020 5:00:10 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/14/2020 8:01:01 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/14/2020 8:00:57 AM
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020 GlobeNewswire Inc. - 2/14/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2020 11:33:23 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/13/2020 9:01:31 AM
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call GlobeNewswire Inc. - 2/13/2020 9:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/10/2020 7:01:09 AM
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre GlobeNewswire Inc. - 2/10/2020 7:00:10 AM
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre GlobeNewswire Inc. - 1/13/2020 6:00:10 AM
Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre GlobeNewswire Inc. - 12/23/2019 8:31:15 PM
Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia... GlobeNewswire Inc. - 11/26/2019 7:55:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/18/2019 8:47:08 AM
Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes GlobeNewswire Inc. - 11/18/2019 8:38:28 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/13/2019 7:56:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/13/2019 7:55:59 AM
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020 GlobeNewswire Inc. - 11/13/2019 7:55:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/7/2019 8:43:15 AM
Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal GlobeNewswire Inc. - 11/7/2019 8:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/6/2019 9:40:07 AM
Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call GlobeNewswire Inc. - 11/6/2019 9:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/4/2019 9:25:45 AM
jammastermike   Tuesday, 04/02/19 06:43:07 PM
Re: jammastermike post# 458
Post # of 734 
well, i meant, phase 3 results being published this fall!!!

glta

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist